{"id":387570,"date":"2026-01-02T20:51:08","date_gmt":"2026-01-02T20:51:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/387570\/"},"modified":"2026-01-02T20:51:08","modified_gmt":"2026-01-02T20:51:08","slug":"drugmaker-known-for-als-medication-to-be-acquired-by-japanese-company-in-2-5b-deal","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/387570\/","title":{"rendered":"Drugmaker known for ALS medication to be acquired by Japanese company in $2.5B deal"},"content":{"rendered":"<p class=\"article__paragraph article__paragraph--left\" id=\"LVA42CENLFHU5AHYUWPKHBQMYQ\">A pharmaceutical company based in New Jersey that\u2019s known for its FDA-approved treatment for ALS is set to be acquired for $2.5 billion. <\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"YTJWG3S6A5FNBCBNO34ONFYR5Q\"><a href=\"https:\/\/us.tanabe-pharma.com\/news-and-media\/press-releases\/2025\/tanabe-pharma-america-announces-transfer-of-radicava-business-to-shionogi\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/us.tanabe-pharma.com\/news-and-media\/press-releases\/2025\/tanabe-pharma-america-announces-transfer-of-radicava-business-to-shionogi\">Tanabe Pharma America<\/a>, which operates a U.S. headquarters in Jersey City, announced Dec. 22 that it reached an agreement with Japanese pharmaceutical company <a href=\"https:\/\/www.shionogi.com\/us\/en\/news\/2025\/12\/shionogi-expands-rare-disease-presence-with-planned-acquisition-of-global-rights-to-tanabe-pharma-corporations-radicava-ors-edaravone-and-iv-radicava.html\" target=\"_blank\" rel=\"noreferrer nofollow noopener\" title=\"https:\/\/www.shionogi.com\/us\/en\/news\/2025\/12\/shionogi-expands-rare-disease-presence-with-planned-acquisition-of-global-rights-to-tanabe-pharma-corporations-radicava-ors-edaravone-and-iv-radicava.html\">Shionogi<\/a> regarding the transfer of global rights to its medication Radicava.<\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"7Z4TTVH4X5BWDFDJNZOYLM3QNE\">As part of the transaction, Tanabe will establish a new U.S. company to manage the Radicava business, which Shionogi will acquire as a wholly owned subsidiary.<\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"PFY63DISAFHZTEYRZRPCUVSLD4\">The acquisition must still receive regulatory approvals. If all goes according to plan, the sale is expected to close in April 2026. <\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"ODNE3O3LRRF43CGTWS2TROLQ3I\">\u201cAs the company that helped bring RADICAVA\u00aeto patients in the United States and Canada, we are incredibly proud of the impact this therapy has had on the ALS community,\u201d said Yasutoshi Kawakami, president of Tanabe, in a press release. <\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"JAR5IKQV6ZGJJIJCVLA4U5CYLY\">\u201cBy transitioning the RADICAVA\u00aebusiness to Shionogi, we believe the product is well positioned to continue reaching patients and caregivers who rely on it, while Tanabe Pharma America sharpens its focus on advancing future therapies,&#8221; Kawakami said. <\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"MPGYOZC6LJBLPAHAKB6Y2RY6DQ\">Company leaders with Shionogi said the acquisition of Radicava represents a commitment to the treatment of rare diseases. <\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"WC4WYWKWQ5GYHEXI27ZXESJK2M\">\u201cWe are very excited to welcome this team and outstanding medicine to our U.S. business. This planned acquisition will solidify our strategic focus in rare disease and immediately add capabilities to ensure long term success in this important category,\u201d said President and CEO Nathan McCutcheon in a press release. <\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"NJJ363ELA5HMNIZZRIDD4RA23E\">\u201cGoing forward, this infrastructure will support future launches in rare disease including Shionogi\u2019s development programs in Fragile X syndrome, Jordan\u2019s Syndrome and Pompe disease,\u201d McCutcheon said. <\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"EOPBVGLPAZDODPGLIHRTQCTFOI\">The company expects the acquisition to boost global sales by approximately $700 million.<\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"D36KBWHJF5F2NEOQFPXCDJS5RY\">Radicava is a prescription medication used to treat ALS, commonly known as Lou Gehrig\u2019s Disease. It\u2019s considered a rare disease, affecting less than 30,000 people in the U.S., according to the Centers for Disease Control and Prevention. The cause is unknown and there\u2019s no cure.<\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"ZABZA63PPZBM5OCX62CU7BUND4\">The FDA first approved an IV version of Radicava in 2017 and an oral version in 2022. <\/p>\n<p class=\"article__paragraph article__paragraph--left\" id=\"BFRA22IGJRAILJD6PUNZ2MYHWU\">It\u2019s one of only four drugs available to people living with the progressive neurodegenerative disease, according to the ALS Association. <\/p>\n","protected":false},"excerpt":{"rendered":"A pharmaceutical company based in New Jersey that\u2019s known for its FDA-approved treatment for ALS is set to&hellip;\n","protected":false},"author":2,"featured_media":387571,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":{"0":"post-387570","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-healthcare"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/387570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=387570"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/387570\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/387571"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=387570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=387570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=387570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}